Загрузка...
Next-generation anti-CD20 monoclonal antibodies in autoimmune disease treatment
The clinical success of anti-CD20 monoclonal antibody (mAb)-mediated B cell depletion therapy has contributed to the understanding of B cells as major players in several autoimmune diseases. The first therapeutic anti-CD20 mAb, rituximab, is a murine–human chimera to which many patients develop anti...
Сохранить в:
| Опубликовано в: : | Auto Immun Highlights |
|---|---|
| Главные авторы: | , , |
| Формат: | Artigo |
| Язык: | Inglês |
| Опубликовано: |
Springer International Publishing
2017
|
| Предметы: | |
| Online-ссылка: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5688039/ https://ncbi.nlm.nih.gov/pubmed/29143151 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s13317-017-0100-y |
| Метки: |
Добавить метку
Нет меток, Требуется 1-ая метка записи!
|